Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

Elżbieta Iskierka-Jażdżewska,Federico Canzian,Anna Stępień,Alessandro Martino,Daniele Campa,Angelica Stein,Malgorzata Krawczyk-Kulis,Malwina Rybicka-Ramos,Slawomira Kyrcz-Krzemien,Aleksandra Butrym,Grzegorz Mazur,Artur Jurczyszyn,Daria Zawirska,Norbert Grząśko,Waldemar Tomczak,Edyta Subocz,Marzena Wątek,Marcin Pasiarski,Marcin Rymko,Malgorzata Calbecka,Agnieszka Druzd-Sitek,Jan Walewski,Marcin Kruszewski,Malgorzata Razny,Jan Maciej Zaucha,Marek Dudziński,Pawel Gaj,Tadeusz Robak,Krzysztof Warzocha,Krzysztof Jamroziak

Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

2019

AbstractCereblon (CRBN) is crucial for antiproliferative and immunomodulatory properties of immunomodulatory drugs. The objective of this study was to verify whether germline single nucleotide poly...

Keywords:

Progression-free survival
Oncology
Immunology
Lenalidomide
Internal medicine
Gene
Diabetes mellitus
Pharmacogenetic Study
Cereblon
Refractory Multiple Myeloma
Germline
Medicine
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations